Showing results (3021-3030 of 3,353) with videos related to
Sort By:
Pageof 336
Pharmacoeconomics|July 1, 2005
Costs and medical care consequences associated with the diagnosis of peripheral arterial diseaseKristen Migliaccio-Walle, J Jaime Caro, Khajak J Ishak, et al.Pharmacoeconomics|September 13, 2005
Economic implications of biological therapies for Crohn's disease: review of infliximabKeith BodgerPharmacoeconomics|September 13, 2005
Cost effectiveness of dalteparin for preventing venous thromboembolism in abdominal surgeryAdrienne Heerey, Sanjeev SuriPharmacoeconomics|June 18, 2005
The cost effectiveness of infliximab for severe treatment-resistant rheumatoid arthritis in the UKMarco Barbieri, John B Wong, Michael DrummondPharmacoeconomics|June 18, 2005
Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary diseaseMichael Spencer, Andrew H Briggs, Ronald F Grossman, et al.Pharmacoeconomics|May 18, 2005
The health-related quality of life and economic burden of constipationCheryl Dennison, Manishi Prasad, Andrew Lloyd, et al.Pharmacoeconomics|May 18, 2005
Cost effectiveness of imatinib compared with interferon-alpha or hydroxycarbamide for first-line treatment of chronic myeloid leukaemiaKim Dalziel, Ali Round, Ruth Garside, et al.Pharmacoeconomics|April 28, 2005
Cost effectiveness of budesonide/formoterol in a single inhaler for COPD compared with each monocomponent used aloneClaes-Göran Löfdahl, Asa Ericsson, Klas Svensson, et al.Pharmacoeconomics|August 16, 2005
An economic evaluation of rizatriptan in the treatment of migraineMelissa Thompson, Marek Gawel, Brigitte Desjardins, et al.Pharmacoeconomics|April 4, 2002
Intermittent claudication: pharmacoeconomic and quality-of-life aspects of treatmentGregorio Brevetti, Roberta Annecchini, Roxanna BucurPageof 336